Our technology

Building Transformative Therapeutics Through Simulation

The unparalleled accuracy of our technology grants unprecedented insights into drug mechanisms, allowing us and our partners to pursue truly groundbreaking therapeutic strategies.

Learn More

Our Mission

Unlocking Undruggable Targets

Our core technology has been built to succeed where status quo in-silico drug design fails. We’ve raised the bar for simulation accuracy, putting previously inaccessible targets and modalities into play.

About Us

Recent News & Events

September 2, 2025

HTuO Biosciences today announced a strategic research collaboration with Micrographia Bio, a UK based biotechnology company. The collaboration, funded by the Canadian Government, will combine Spatial Proteomics and CADD tools to develop next-generation small molecule osteoporosis drug.

August 27, 2025

HTuO Biosciences will be presenting at Life Science BC’s Invest in BC, presented by Lumira Ventures, on October 28 and 29, 2025. During the event, our CEO, Dr. Anthony Fejes, will be sharing our progress and exciting future opportunities.

June 3, 2025

We are excited to announce our CEO, Dr. Anthony Fejes will take the stage at the BIOTECanada Coast-to-Coast competition at BIO 2025, on Wednesday, June 18 at 10AM in Boston. This unique event highlights five promising biotech companies from across Canada, each delivering a focused, no-slide pitch to a panel of leading investors and pharma executives.

View All News & Events
Team Image

Interested in working with us?

Join the HTuO Team

Check our Careers page for open positions, and see if we have the right opportunity for you.

Open Positions